ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition
On August 14, 2017, Eleven Biotherapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 2.02 Financial Statements and Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
|
99.1 |
Press release issued by the Company on August 14, 2017 |
Eleven Biotherapeutics, Inc. ExhibitEX-99.1 2 q22017prvfinal.htm EXHIBIT 99.1 Exhibit Eleven Biotherapeutics Reports Second Quarter 2017 Financial Results– Announced Data and Safety Monitoring Board Recommendation to Continue Phase 3 Registration Trial of Vicinium™ as Planned — — Entered Collaboration with National Cancer Institute and AstraZeneca to Evaluate Vicinium in Combination with ImfinziTM (Durvalumab) in Patients with Non-Muscle Invasive Bladder Cancer —- Management to Host Conference Call Today at 8:00 a.m. ET — CAMBRIDGE,…To view the full exhibit click here
About ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO)
Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).
